Lexeo Therapeutics Inc [LXEO] stock is trading at $2.14, up 8.08%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The LXEO shares have gain 19.55% over the last week, with a monthly amount drifted -30.29%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lexeo Therapeutics Inc [NASDAQ: LXEO] stock has seen the most recent analyst activity on June 13, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $28. Previously, H.C. Wainwright started tracking the stock with Buy rating on June 06, 2024, and set its price target to $22. On November 28, 2023, Stifel initiated with a Buy rating and assigned a price target of $20 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $22 on November 28, 2023. Leerink Partners initiated its recommendation with a Outperform and recommended $19 as its price target on November 28, 2023. JP Morgan started tracking with a Overweight rating for this stock on November 28, 2023, and assigned it a price target of $20. In a note dated November 28, 2023, Chardan Capital Markets initiated an Buy rating and provided a target price of $23 on this stock.
Lexeo Therapeutics Inc [LXEO] stock has fluctuated between $1.45 and $19.50 over the past year. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. Lexeo Therapeutics Inc [NASDAQ: LXEO] shares were valued at $2.14 at the most recent close of the market. An investor can expect a potential return of 1208.41% based on the average LXEO price forecast.
Analyzing the LXEO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.67, Equity is -0.65 and Total Capital is -0.85. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.0000 points at the first support level, and at 1.8700 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.2400, and for the 2nd resistance point, it is at 2.3400.
Ratios To Look Out For
For context, Lexeo Therapeutics Inc’s Current Ratio is 5.52. As well, the Quick Ratio is 5.52, while the Cash Ratio is 1.53.
Transactions by insiders
Recent insider trading involved Townsend Richard Nolan, Chief Executive Officer, that happened on Feb 19 ’25 when 4326.0 shares were sold. Chief Development Officer, See Tai Sandi completed a deal on Feb 19 ’25 to sell 1486.0 shares. Meanwhile, Chief Medical Officer Adler Eric sold 2359.0 shares on Feb 19 ’25.
